Recent Updates
Recently added Catalysts
WAT Positive Sentiment

Waters Takes Targeted, Quantitative Imaging to the Next Level with New DESI Source for the Xevo TQ Absolute System American Society for Mass Spectrometry (ASMS) -- Waters Corporation (NYSE:WAT) today launched the industry's first targeted imaging mass spectrometer ...

Key Takeaway: Waters Corporation has unveiled the first targeted imaging mass spectrometer, integrating its Xevo TQ Absolute system with a new DESI XS source. This innovative instrument boasts five times the sensitivity and speed compared to existing systems, allowing for precise drug targeting within biological tissues. The new capabilities will aid scientists in efficiently evaluating drug effects and meeting stringent regulatory standards in their research efforts. Waters continues to lead advancements in analytical technologies for life sciences applications.
Price reaction · baseline $258.77 (2023-06-02 close) · clean, no other WAT news in the window
day 0 close
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • The new imaging mass spectrometer offers five times increased sensitivity and speed.
  • The DESI XS source enhances the efficiency of drug evaluation at targeted sites.
  • Waters is at the forefront of innovation in analytical instruments for drug development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~19 mo
Low dilution risk
Lead asset
CYTALUX preoperatively
Phase 2 · Esophageal Cancer

Full Press Release Details

HOUSTON , June 5, 2023 /PRNewswire/ -- American Society for Mass Spectrometry (ASMS) -- Waters Corporation (NYSE: WAT ) today launched the industry's first targeted imaging mass spectrometer based on its Xevo™ TQ Absolute tandem quadrupole mass spectrometer, the most sensitive and compact mass spectrometer in its class. The new instrument combines the Waters™ DESI XS source with the Xevo TQ Absolute system and is five times more sensitive and five times faster than discovery-based imaging systems at precisely determining whether a particular small molecule drug product – and how much of it - reaches its intended target, such as a brain, liver, or lung, in a test subject.
Waters adds DESI XS source to its Xevo TQ Absolute mass spectrometer for fast and sensitive targeted MS imaging.
"Customers have successfully applied the Xevo TQ Absolute system to solve a host of problems including PFAS testing at parts-per-quadrillion levels," said Jon Pratt , Senior Vice President, Waters Division. "Now, combining it with the DESI XS source gives drug development scientists a powerful new tool for efficiently evaluating the effects of drugs at the site of action with the statistical power of full studies."
Dr. Jephte Akakpo , Post-Doctoral Research Fellow, University of Kansas Medical Center , is part of a team researching an antidote (fomepizole) to drug–induced acute liver and kidney damage caused by an acetaminophen overdose.
"The DESI XS source features a high-performance sprayer and that makes the DESI source robust so we can work much more efficiently," said Dr. Akakpo. "Pairing it with the Xevo TQ Absolute system will greatly improve the signal-to-noise ratio and lets us test hypotheses in a way that we couldn't before. The system is taking quantitative MS imaging to the next level."
Applications for direct-from-sample DESI/tandem quadrupole mass spectrometry include:
At this year's ASMS conference, Waters is also showcasing its PFAS analytical workflow based on the ultra-sensitive Xevo TQ Absolute mass spectrometer, chemistries, and software. The end-to-end UPLC-MS workflow allows laboratories worldwide to upgrade their capability and keep current with the latest regulatory requirements for measuring parts-per-quadrillion levels of PFAS in air, water, soil, and food.
Additional Resources
About Waters Corporation ( www.waters.com )
Waters Corporation (NYSE: WAT ), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With more than 8,200 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters and Xevo are trademarks of Waters Corporation.
Waters Contact:
Brian J. Murphy PR Manager, Corporate Communications Waters Corporation [email protected] +1 508-482-2614
i Comparison to Waters high resolution MALDI or DESI-enabled discovery quadrupole time-of-flight MS imaging systems. ii Targeted Desorption Electrospray Ionization Mass Spectrometry Imaging for Drug Distribution, Toxicity, and Tissue Classification Studies doi: 10.3390/metabo13030377

Frequently Asked Questions

What is the new mass spectrometer by Waters Corporation?

Waters Corporation launched the Xevo™ TQ Absolute, the industry's first targeted imaging mass spectrometer.

How does the Xevo TQ Absolute compare to other systems?

It is five times more sensitive and faster than conventional imaging systems.

What is the benefit of the DESI XS source?

The DESI XS source enhances the system's robustness, improving signal-to-noise ratios for better testing.

What applications does the new system support?

It supports drug testing and quantitative MS imaging, enhancing evaluations at drug action sites.

What is the purpose of the PFAS analytical workflow?

It helps labs detect PFAS at parts-per-quadrillion levels, meeting regulatory standards.

Last updated: Jun 5, 2023